Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Heparin binds to antithrombin III (ATIII) via a unique pentasaccharide sequence, inducing a conformational change that accelerates ATIII-mediated inactivation of coagulation factors IIa (thrombin), Xa, IXa, XIa, and XIIa. The heparin-ATIII complex primarily inhibits thrombin and factor Xa, with higher molecular weight heparin more effectively inactivating thrombin.
Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.
Prophylaxis and treatment of venous thromboembolism (VTE) including deep vein thrombosis (DVT) and pulmonary embolism (PE),Treatment of acute coronary syndromes (unstable angina, non-ST-elevation MI),Anticoagulation for atrial fibrillation, cardioversion, and during pregnancy,Anticoagulation in extracorporeal circuits (e.g., hemodialysis, cardiopulmonary bypass),Off-label: Anticoagulation for acute ischemic stroke in select patients, prevention of left ventricular thrombus post-MI
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis),Adjunctive therapy in acute bronchial asthma and status asthmaticus,Off-label: Treatment of apnea of prematurity
For therapeutic anticoagulation, administer 18 units/kg/hour intravenous infusion after a bolus of 80 units/kg. For prophylactic dosing, 5000 units subcutaneously every 8 to 12 hours.
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.
Terminal half-life: 1-2 hours (dose-dependent: 30-60 min after IV bolus 100 U/kg, up to 2-3 hours with higher doses or continuous infusion). Clearance is biphasic; prolonged in hepatic/renal impairment.
Terminal elimination half-life: 3-12 hours in adults (mean 5-6 hours); prolonged in hepatic impairment, heart failure, COPD, and neonates (up to 30 hours). Smoking reduces half-life by 30-50%.
Heparin is metabolized by the liver (heparinase) and to a lesser extent by the reticuloendothelial system. It is also partially depolymerized and desulfated. The clearance is dose-dependent and involves both saturable (cellular uptake and metabolism) and non-saturable (renal excretion) mechanisms. Heparin is partially excreted unchanged in urine.
Theophylline is metabolized primarily in the liver by cytochrome P450 isoenzymes, predominantly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism involves N-demethylation and oxidation. In neonates, metabolism is immature; in adults, ~90% is hepatically cleared. Ethylenediamine is minimally metabolized.
Renal: 40-60% unchanged via urine (dose-dependent saturable mechanism); hepatic: minimal; fecal: negligible.
Renal excretion of unchanged drug (about 10-20%) and metabolites (primarily 1,3-dimethyluric acid, 1-methyluric acid, 3-methylxanthine). Billary/fecal excretion is negligible.
Highly bound to antithrombin III (ATIII) and other plasma proteins (e.g., albumin, lipoproteins); non-specific binding ~95% at therapeutic concentrations (saturable).
Theophylline (active moiety): approximately 40% bound to plasma proteins, primarily albumin. Protein binding decreases in neonates, hepatic cirrhosis, and uremia.
Vd: 0.05-0.07 L/kg (confined to plasma volume; ~5-7 L in adults). Clinical meaning: low Vd indicates minimal extravascular distribution; primarily intravascular binding to ATIII and endothelial cells.
Apparent volume of distribution: approximately 0.4-0.6 L/kg (average 0.45 L/kg). Indicates distribution into total body water; slightly higher in neonates and premature infants.
SC: 20-30% (dose-dependent, lower with higher doses due to saturable absorption); IV: 100%; not administered orally (negligible absorption).
Oral: 96-100% for immediate-release tablets; 50-70% for some sustained-release formulations depending on formulation. Rectal: 70-80% (variable). IV: 100%.
No specific GFR-based dose reduction required; heparin is not renally cleared. Monitor a PTT and adjust per protocol.
No dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce maintenance dose by 50% and monitor serum theophylline levels. For GFR <10 m L/min: reduce maintenance dose by 50% and extend dosing interval or use with caution.
No Child-Pugh based dosing recommendations; use with caution in severe hepatic impairment due to increased bleeding risk. Monitor a PTT closely.
Child-Pugh A: reduce dose by 50%. Child-Pugh B: reduce dose by 75%. Child-Pugh C: contraindicated or use with extreme caution, reduce dose by 80% and monitor levels.
Loading dose: 75-100 units/kg intravenously over 10 minutes. Maintenance infusion: initial 28 units/kg/hour for infants <1 year, 20 units/kg/hour for children >1 year; adjust to target a PTT.
Loading dose: 1 mg/kg IV (if not on theophylline). Maintenance: Continuous infusion: age 6 months-1 year: 0.5 mg/kg/h; age 1-9 years: 0.8 mg/kg/h; age 9-12 years: 0.7 mg/kg/h; age 12-16 years: 0.6 mg/kg/h. Maximum daily dose: 24 mg/kg/day.
Elderly patients may have reduced heparin clearance; lower initial infusion rates (e.g., 15 units/kg/hour) and more frequent a PTT monitoring recommended to avoid over-anticoagulation.
Consider lower initial doses due to decreased clearance. Use ideal body weight. Start at lower maintenance infusion rate (e.g., 0.3 mg/kg/h) and titrate based on serum levels and clinical response. Monitor for toxicity.
Heparin is not recommended for use as an anticoagulant in patients with a history of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITT). Monitor platelet counts closely. Risk of bleeding, especially in patients with risk factors. Use preservative-free heparin for neonatal patients to avoid benzyl alcohol toxicity.
None
Risk of heparin-induced thrombocytopenia (HIT) type II, immune-mediated; monitor platelet counts every 2-3 days from day 4 to 14 or until heparin stopped,Risk of bleeding: elderly, renal impairment, concomitant antiplatelet agents,Heparin resistance (antithrombin III deficiency, elevated factor VIII),Hyperkalemia due to aldosterone suppression (risk increased with renal impairment, diabetes, potassium-sparing diuretics),Spinal/epidural hematoma risk with neuraxial anesthesia; monitor for neurological compromise,Do not administer intramuscularly due to risk of hematoma,Use with caution in patients with severe hypertension, recent surgery, gastrointestinal ulcers, or hemorrhagic stroke
Narrow therapeutic index; serum theophylline levels must be monitored to avoid toxicity. Risk of seizures, cardiac arrhythmias, and death, especially at high serum concentrations. Caution in patients with hepatic impairment, congestive heart failure, cor pulmonale, fever, and in the elderly. Drug interactions with cimetidine, fluoroquinolones, macrolides, oral contraceptives, and other CYP1A2 inhibitors can increase toxicity.
Absolute: History of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) (heparin), known hypersensitivity to heparin or pork products (if porcine-derived), active major bleeding (except when due to disseminated intravascular coagulation), severe uncontrolled bleeding disorders (e.g., hemophilia), suspected intracranial hemorrhage, epidural or spinal puncture within 24 hours (for full-dose anticoagulation),Relative: Severe thrombocytopenia (platelet count <50,000/μL), uncontrolled severe hypertension, recent surgery (especially brain, spinal, or eye), active gastrointestinal ulcer or bleeding, hemorrhagic stroke (acute), pericarditis with effusion, bacterial endocarditis, threatened abortion, severe renal or hepatic impairment, advanced age (>60-70 years)
Absolute: Hypersensitivity to theophylline, ethylenediamine, or any component; use in patients with active seizure disorder (unless receiving appropriate anticonvulsant therapy); use in patients with a history of ventricular arrhythmias (except under close supervision). Relative: Peptic ulcer disease, hyperthyroidism, hypertension, and renal impairment.
No direct food interactions. Avoid excessive consumption of vitamin K-rich foods (e.g., leafy greens) if transitioning to warfarin, as it may affect INR.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they can potentiate theophylline effects and increase risk of toxicity. A high-protein diet may increase theophylline clearance; maintain consistent dietary habits.
Heparin does not cross the placenta; no evidence of teratogenicity in any trimester. FDA pregnancy category C (due to risk of maternal hemorrhage).
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only if benefit outweighs risk; may cause fetal tachycardia or irritability due to adenosine receptor blockade. Avoid near term due to potential neonatal irritability.
Heparin is not excreted into breast milk due to high molecular weight; compatible with breastfeeding. M/P ratio: negligible.
Not recommended unless essential. Aminophylline is excreted into breast milk; M/P ratio approximately 0.6–0.8. Monitor infant for irritability or insomnia. Consider alternative therapies if breastfeeding.
Pregnancy increases plasma volume and renal clearance; may require higher doses to achieve therapeutic a PTT. Individualize based on a PTT monitoring; subcutaneous doses may need to be increased by 10-20% or more.
Pregnancy may decrease protein binding and increase clearance of theophylline; monitor serum levels closely. Dose may need to be increased by 10–30% to maintain therapeutic levels. Postpartum, doses may need reduction.
For heparin infusion, monitor a PTT 6 hours after initiation or dose change; goal typically 1.5-2.5 times control. Use weight-based dosing (e.g., 18 units/kg/hr). Avoid intramuscular injections due to hematoma risk. Check platelet counts for heparin-induced thrombocytopenia (HIT) every 2-3 days. Protamine sulfate reverses heparin at a ratio of 1 mg per 100 units.
Aminophylline is a bronchodilator used primarily for asthma and COPD exacerbations. Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Administer IV infusion over 30 minutes to avoid hypotension. Caution in patients with cardiac arrhythmias, hyperthyroidism, or seizure disorders. Drug interactions include cimetidine, fluoroquinolones, and macrolides which increase theophylline levels.
Report any unusual bleeding, bruising, or dark stools.,Inform all healthcare providers that you are on heparin.,Use an electric razor and soft toothbrush to avoid injury.,Do not take aspirin or NSAIDs without doctor approval.,Notify your doctor if you experience chest pain, shortness of breath, or leg swelling.
Take this medication exactly as prescribed; do not stop or change dose without consulting your doctor.,Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects like jitteriness and palpitations.,Report any symptoms of toxicity such as nausea, vomiting, insomnia, rapid heart rate, or seizures immediately.,Inform your healthcare provider of all other medications, especially antibiotics, heart medications, or seizure drugs.,Do not chew or crush the solution; it is for intravenous use only under medical supervision.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, answered by our medical review team.
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% is a Electrolyte that works by Heparin binds to antithrombin III (ATIII) via a unique pentasaccharide sequence, inducing a conformational change that accelerates ATIII-mediated inactivation of coagulation factors IIa (thrombin), Xa, IXa, XIa, and XIIa. The heparin-ATIII complex primarily inhibits thrombin and factor Xa, with higher molecular weight heparin more effectively inactivating thrombin.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% is: For therapeutic anticoagulation, administer 18 units/kg/hour intravenous infusion after a bolus of 80 units/kg. For prophylactic dosing, 5000 units subcutaneously every 8 to 12 hours.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% is classified as Category A/B. Heparin does not cross the placenta; no evidence of teratogenicity in any trimester. FDA pregnancy category C (due to risk of maternal hemorrhage).. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.